Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 9/20 | 0.89 |
| ▸ | ITGA2 | P17301 | 7/20 | 0.89 |
| ▸ | ITGAV | P06756 | 1/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 6/20 | 0.44 |
| ▸ | MMP3 | P08254 | 5/20 | 0.44 |
| ▸ | MMP7 | P09237 | 5/20 | 0.44 |
| ▸ | MMP13 | P45452 | 5/20 | 0.44 |
| ▸ | MMP2 | P08253 | 3/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253453 | 0.94 | ITGB1 (1.00) | ITGB1ITGA2ITGAVITGA4MMP1 | |
| SCHEMBL31001648 | 0.94 | ITGB1 (1.00) | ITGB1ITGA2ITGAVITGA4MMP1 | |
| SCHEMBL21376388 | 0.94 | ITGB1 (1.00) | ITGB1ITGA2ITGAVITGA4MMP1 | |
| SCHEMBL12084520 | 0.94 | ITGB1 (1.00) | ITGB1ITGA2ITGAVITGA4MMP1 | |
| SCHEMBL1487440 | 0.92 | ITGB1 (0.90) | ITGB1ITGA2ITGAVITGA4MMP1 | |
| SCHEMBL1487388 | 0.92 | ITGB1 (0.89) | ITGB1ITGA2ITGAVITGA4MMP1 | |
| SCHEMBL1487415 | 0.92 | ITGB1 (0.89) | ITGB1ITGA2ITGAVITGA4MMP1 | |
| SCHEMBL1487437 | 0.90 | ITGB1 (0.84) | ITGB1ITGA2ITGAVITGA4MMP1 | |
| SCHEMBL1487451 | 0.88 | ITGB1 (0.82) | ITGB1ITGA2ITGAVITGA4MMP1 | |
| SCHEMBL1487435 | 0.88 | ITGB1 (0.84) | ITGB1ITGA2ITGAVITGA4MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910609-B2 | Inhibitors of integrin alpha2beta1 with modified urea moiety | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-03-22 | — | — | US | claimed |
| US-20090197861-A1 | INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | claimed |
| US-7910609-B2 | Inhibitors of integrin alpha2beta1 with modified urea moiety | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090197861-A1 | INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197861-A1 | INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY | ITGA2B, ITGA2, ITGB2 | ITGB1 4/4885ITGA2 2/4885ITGAV 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.